Under pressure overload, initial adaptive hypertrophy of the heart is followed by cardiomyocyte elongation, reduced contractile force, and failure. The mechanisms governing the transition to failure are not fully understood. Pressure overload reduced cardiac myosin light chain kinase (cMLCK) by 80% within 1 week and persists. Knockdown of cMLCK in cardiomyocytes resulted in reduced cardiac contractility and sarcomere disorganization. Thus, we hypothesized that acute reduction of cMLCK may be causative for reduced contractility and cardiomyocyte remodelling during the transition from compensated to decompensated cardiac hypertrophy.
Introduction
In the clinical setting, patients with heart failure suffer extremely high rates of mortality, with up to half dying within 4 years of diagnosis, a progression greater than that for cancer. 1 Despite the development of new and more effective therapies, heart failure remains the leading cause of cardiac death. 2 Under sustained pressure overload, hearts initially exhibit adaptive cardiomyocyte hypertrophy, followed by transitions to failure characterized by maladaptive elongation of cardiomyocytes, and persistent reductions in contractile force. This progression in remodelling is thought to involve an initial adaptive addition of sarcomeres in parallel, producing thickening, and a subsequent addition of sarcomere in series, leading to elongation. 3 -6 It is not known, however, whether the addition of sarcomeres occurs in adults in the context of the semi-crystalline architecture of mature cardiomyocytes and the continued production of myocardial force. 3 -6 Studies in the past several decades have shown that the phosphorylation of cardiac myosin light chain 2v (MLC2v) potentiates the rate and force of contraction in the heart. 7 -13 The predominant kinase for MLC2v, cardiac myosin light chain kinase (cMLCK), encoded by the Mylk3 gene, was identified several years ago, 14, 15 and confirmed as the predominant MLC2 kinase in vivo. 16, 17 In cultured cardiomyocytes, overexpression of cMLCK facilitates sarcomeric organization, while its knockdown results in sarcomeric disorganization. 15 A reduction in cMLCK protein was demonstrated as early as 1 week after induction of pressure overload by murine aortic banding or transverse aortic constriction (TAC), which was shown to coincide with the functional transition from compensated to decompensated hypertrophy within 1-2 weeks of the banding. 17 Unexpectedly, germline cMLCK-deficient (Mylk3 2/ 2 ) mice exhibited compensated cardiac hypertrophy and only moderate heart failure. The mice, however, progressed to severe heart failure under pressure overload. 17 In the current study, in order to mimic the acute reduction of cMLCK in heart failure, and to understand its effect during transition to heart failure, we have generated tamoxifen-inducible adult Mylk3 knockout mice. As in the mice that transitioned rapidly to heart failure subsequent to banding-induced pressure overload, we found that our adult Mylk3 knockout mice also suffered a rapid onset of heart failure.
Methods

Generation of mouse models
A conditional null allele of Mylk3 was generated as described previously. 17 Germline transmitted mice were crossed with ACTB-Cre transgenic mice (Jackson Laboratory, Bar Harbor, ME, USA) to eliminate the floxed-neomycin-resistant gene. Mice heterozygous for a floxed-Mylk3 allele were bred to those expressing the EIIa-Cre transgene (Jackson Laboratory, Bar Harbor, ME, USA), resulting in a germline Mylk3 flox/+ allele. These mice were bred to aMHCmerCremer mice, 18 followed by cross-breeding to generate Mylk3 +/ + and Mylk3 flox/flox with or without the aMHCmerCremer transgene on a mixed genetic background, mainly C57BL/6. The mice were used at 10 -12 weeks of age, with only female mice being subjected to physiological analyses in order to eliminate gender differences in cardiac function. Mice were sacrificed under isoflurane deep anaesthesia or CO 2 inhalation. The TAC operation was performed under sodium pentobarbital anaesthesia (40-60 mg/kg, i.p.), as described previously. 17, 19 All animal procedures were performed to conform the NIH guidelines (Guide for the Care and Use of Laboratory Animals) and approved by the University of Florida Institutional Animal Care and Use Committee.
MRI, echocardiography, and left ventricular pressure-volume measurement
Mice were anaesthetized with 1.5 -2% isoflurane supplied either through a nose cone for MRI and echocardiography, or through tracheal intubation for left ventricular pressure-volume (LVPV) measurement. MRI and echocardiography of the hearts were performed as described previously, 17 except for using CINE and HARP software analyses (Diagnosoft, Durham, NC, USA). LVPV measurements using a Millar catheter were performed using standard methods 20 and analysed by PVAN TM as previously described, 19 followed by the conversion of relative volume units to units of volume using the cuvette calibration.
2.3 Measurements of cardiomyocyte size, simultaneous measurements of cell shortening, and intracellular free calcium
Isolated adult cardiomyocytes attached to glass coverslips were imaged under a microscope and digitized for measurements of cell surface area.
Rod-shaped cardiomyocytes with clear cross-striations, staircase ends, and surface membranes free from blebs were used for simultaneous measurements of cell shortening and intracellular free calcium (IonOptics, Westwood, MA, USA), as described previously. 
Statistical analyses
Data presented are expressed as mean values + SEM. The data, including more than two levels of a repeated-measures factor, were analysed for normal distribution by Levene's test for equality of variances (SPSS ver. 23). Results were compared using Student's t-test, ANOVA with or without repeated-measures analyses, nested ANOVA, and Fisher's post hoc test. A value of P , 0.05 was considered significant (see Supplementary material online, Table S1 for additional information).
Results
Acute heart enlargement in adult-onset inducible Mylk3-KO mice
To mimic the effects of cMLCK reduction observed following TAC, 17 we generated acute Mylk3-KO in adult mice using the tamoxifen-inducible Cre recombinase system ( Figure 1A) . Deletion of the floxed exon 5 resulted in elimination of the first coding exon of the catalytic domain and a frameshift of the subsequent downstream exons. In addition, deletion of exon 5 resulted in reduction of cMLCK mRNA, 17 attributable to a nonsense-mediated mRNA decay, 22 with targeted cMLCK mRNA containing a premature termination codon. In this study, the effect of tamoxifen-inducible deletion of the Mylk3 gene in Mylk3 flox/flox /aMHCmerCremer mice, hereafter Mylk3-KO, was examined and compared with two control mice (Mylk3 flox/flox and Mylk3 +/ + /merCremer) following tamoxifen injection (50 mg/kg/day, 2 consecutive days). This dose of tamoxifen was substantially below the previously reported level of toxicity (i.e. 80 mg/kg/day × 5 days). 23 Day 0 is taken as the day of the first injection ( Figure 1B ).
Expression of cMLCK protein was reduced by Day 4 and was below the level of detection on Day 6 in Mylk3-KO following tamoxifen injection ( Figure 1C ). On Day 6, the phosphorylation of the known cMLCK substrate, MLC2v, was markedly reduced in the Mylk3-KO hearts ( Figure 1D ). The time course in the reduction in cMLCK protein and MLC2 phosphorylation is shown in Figure 1E .
On Day 7, hearts were enlarged in Mylk3-KO mice ( Figure 2A ). In particular, when the heart was fixed at end-diastole by retrograde perfusion, the ventricles were noted to be markedly distended, with thinner walls in the hearts from Mylk3-KO mice on Days 7 and 14 compared with their controls ( Figure 2B ). The heart weight/body weight (HW/BW) ratio was increased in Mylk3-KO compared with control Mylk3 flox/flox mice ( Figure 2C ). In contrast, Mylk3 +/+ /merCremer control mice did not show any increase in the HW/BW ratio on Day 14 following tamoxifen injection ( Figure 2D and Figure 3B and see Supplementary material online, Figure S1 ). Increased expression of fetal genes, including ANF, BNP, and skeletal actin, is often observed in failing hearts and was demonstrated in the hearts from Mylk3-KO mice on Day 7 ( Figure 2E ).
Contractile dysfunction in Mylk3-KO mice on Day 7
Detailed cardiac function in vivo was analysed on Day 7 using MRI, echocardiography, and the left ventricular pressure volume (LVPV) relationship. Representative images obtained using MRI showed increased size of the left and right ventricular cavities at end-diastole in Mylk3-KO mice compared with their age-and sex-matched controls (Mylk3 flox/flox with tamoxifen injection; Figure 3A ). The hearts from Mylk3-KO mice demonstrated statistically increased volumes of the left ventricular cavity both at end-systole and at end-diastole. Decreases in ejection fraction, wall thickness at end-diastole, per cent changes in wall thickness in end-systole compared with that at end-diastole, and reduced cardiac torsion, seen as reduced twisting motion, were also observed in Mylk3-KO mice ( Figure 3A) . Echocardiography was performed on Days 0, 7, and 14 after injection of tamoxifen in both Mylk3-KO mice and their two control groups ( Figure 3B and see Supplementary material online, Figure S1 ). Consistent with the MRI studies, there were reductions in cardiac contractility and increases in the dimensions of the left ventricular cavity both on Days 7 and 14 after injections of tamoxifen in Mylk3-KO mice, but not in the two control groups. Further analyses showed that reduction of contractility started as early as Day 4 using serial echocardiography, corresponding to the reduction of cMLCK protein expression ( Figures 3C and 1C) .
Haemodynamic measurements by left ventricular catheterization showed that Mylk3-KO mice exhibited reduced rates of contraction (+dP/dt) and relaxation (2dP/dt), increased left ventricular volume, and markedly reduced preload recruitable stroke work, which defines LV performance independently from the loading conditions ( Figure 3D) . Overall, detailed functional analyses on Day 7 after tamoxifen injection showed that Mylk3-KO mice were in acute heart failure with reduced contractility.
3.3 Cardiomyocyte atrophy, cell death, and impaired Ca 21 handling in Mylk3-KO mice
Histological analyses revealed severely convoluted, and wavy, cardiomyocytes, which had an abnormal sarcomeric structure, along with increased fibrosis in the hearts from Mylk3-KO mice when compared with their controls (Figure 4A-C) . The number of TUNEL-positive nuclei Acute heart failure in inducible Mylk3 knockout relative to the total nuclei is also increased in Mylk3-KO mice compared with the controls (Figure 4D) , suggesting additional involvement of apoptosis for cell death.
When the heart was arrested and fixed at end-diastole by retrograde perfusion, the wavy cardiomyocytes were found to be more straight, elongated, and thinner than controls ( Figure 4E) . TEM from the hearts arrested and fixed at end-diastole revealed the anticipated alignment of adjacent sarcomeres in the control hearts, but not in the hearts from Mylk3-KO mice ( Figure 4F ). In the Mylk3-KO mice, sarcomeres were thinner, and the width of single sarcomeres varied within a single myocyte. Consistently, cardiomyocytes isolated from Mylk3-KO mice were longer and thinner than their controls, showing an increased ratio between their long and short axes ( Figure 5A ). They also showed marked reductions in contractility and rates of contraction and relaxation ( Figure 5B Acute heart failure in inducible Mylk3 knockout SERCA2a and phospholamban was uniquely demonstrated in inducible Mylk3-KO, but not in germline Mylk3 2/2 mice ( Figure 5C ). Western blotting confirmed the reduction of SERCA2a in inducible Mylk3-KO and oppositely a slight increase in Mylk3 2/ 2 mice ( Figure 5D ). Expression of SERCA2a's negative regulator, phospholamban, was reduced in inducible Mylk3-KO mice. The degree of its reduction, however, was less than that of SERCA2a, and was not specific in inducible Mylk3-KO mice, as seen in germline Mylk3 2/2 mice except for the total pentameric form of phospholamban ( Figure 5D ). Figure 6A ). Consistent with that finding, there were no compensatory increases of mRNA of these kinases in either inducible or germline Mylk3 knockout mice ( Figure 6B ). -phosphorylated and total phospholamban expression in inducible and germline Mylk3 knockout mice relative to GAPDH with the value in Mylk3 flox/flox defined as 1 (mean + SEM, n ¼ 3 each). *P , 0.05.
Attenuation of pressure overload hypertrophy in Mylk3-KO mice
Finally, in order to examine whether reduction of cMLCK is involved in the transition from initial adaptive thickening of cardiomyocytes to a subsequent elongation, 3 -6 we subjected the Mylk3-KO mice to transaortic constriction (TAC) on Day 4 when cMLCK expression was markedly reduced. We then examined for the presence of anticipated adaptive cardiomyocytic thickening on Day 9 ( Figure 6C ). Adaptive thickening, as revealed by an increase in short axis width and increased cell area, was observed in control mice after 5 days of sustained pressure overload. In contrast, the cardiomyocytes from Mylk3-KO mice were further elongated, showing no evidence of thickening ( Figure 6D and E).
Discussion
Our major finding is that rapid, progressive, and profound heart failure, accompanied by sarcomeric atrophy, occurs shortly after elimination of cMLCK in adult mice. Pressure overload did not induce adaptive cardiomyocyte thickening in the absence of cMLCK. MLC2 phosphorylation, which has been shown to stabilize the actin -myosin interaction, 7 -13 was markedly reduced or absent in inducible Mylk3-KO and germline Mylk3 2/2 mice corresponding to the absence of cMLCK.
There was no significant induction of other potential MLC2v kinases, including skeletal and smooth muscle MLCK, and Dapk3/ZIPK3. 8, 26, 27 In human heart failure, MLC2v phosphorylation is known to be reduced from 30 to 40% in healthy hearts to 18% of total MLC2v. 28, 29 Severely convoluted cardiomyocytes with sarcomeric disorganization, wavy fibres, and cell death were demonstrated in Mylk3-KO mice, and prevented normal contractile forces, thus leading to heart failure. The pathological finding named 'attenuated wavy fibre' is sometimes observed in acute and chronic heart failure in humans and animal models. 30 -34 It is extensively recognized in canine species as one of the criteria for dilated cardiomyopathy. 32, 35 The underlying mechanism is not fully understood, and the waviness may be an artefact in vitro, reflecting the loss of volume distention. This partly agrees with findings in Mylk3-KO mice, in which waviness was not evident with light microscopy when the heart was arrested and fixed at the diastole. TEM analysis following perfusion fixation, however, did not show the anticipated alignment of sarcomeres in the hearts from Mylk3-KO mice, suggesting that attenuated wavy fibres might reflect additional specific disease processes. Acute heart failure in inducible Mylk3 knockout Intracellular Ca 2+ homeostasis is well balanced in normal hearts, but is altered in a number of human and rodent heart failure models, and is responsible for depressed contractility. 36 -38 In Mylk3-KO mice, solely be due to the absence of rapid and inducible phosphorylation of MLC2, or due to the absence of cMLCK itself in adult mice. For instance, kinase-independent functions have been well established in cytoskeletal organization, cell migration, aggregation, and cell membrane tension in smooth muscle MLCK, primarily due to the F-actin binding of smooth muscle MLCK through a repeat motif (DFRXXL). 43 -45 cMLCK, however, does not contain the putative F-actin binding DERXXL motif 15 and does not bind to cardiac actin (data not shown). These possibilities, which are beyond the scope of the current study, require additional future investigations. To mitigate the possibility that a high dose of tamoxifen, such as 80 mg/kg/day given over 5 days (total 400 mg/kg), would result in heart failure, 23 we utilized a substantially lower dose, specifically 50 mg/kg/ day given over 2 days. Furthermore, we included a second control, Mylk3 +/+ /merCremer mice, which showed no change in the ratio between HW/BW, nor contractility, subsequent to injection of tamoxifen. Consistently, the total amount of tamoxifen we used in the current study, namely 100 mg/kg, is below the level known to produce cardiac toxicity and within the recommended doses as shown in multiple studies. These values were a total of 80-120 mg/kg, with 20 mg/ kg/day given over 4 -6 days as described in the original study which generated and characterized aMHCmerCremer mice, 18 and a total of 120 mg/kg, with 40 mg/kg/day given over 3 days. 46 Pressure overload by TAC is widely used to evoke hypertrophy in animal models so as to understand the processes of cardiac remodelling. In the clinical setting, however, left ventricular pressure overload occurs more chronically, as seen in long-standing systemic hypertension or left ventricular outflow tract obstruction. The difference between the experimental and clinical settings represents one of the limitations of the experimental design of the current study. To understand the role of cMLCK in TAC-induced cardiac hypertrophy, pressure overload was initiated on Day 4 following tamoxifen injection, when expression of cMLCK protein begins to be markedly reduced. At the same time, cardiac contractility starts to decline rapidly. Thus, the interpretation of the data regarding the absence of TAC-induced cardiac hypertrophy in inducible Mylk3-KO mice also needs to take account of the complex secondary effects resulting from the heart failure itself.
In summary, we have created novel adult inducible Mylk3-KO mice, which suffer rapid and profound heart failure. In these mice, furthermore, pressure overload did not induce initial adaptive cardiomyocytic thickening. Our findings suggest that the mouse model is likely to provide important insights into the molecular mechanisms underlying the transition from adaptive hypertrophy to heart failure by pressure overload.
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